Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- SARSCoV beta anti coronavirus SARSCoV2 CoV2 COVID19 nucleo protein capsid novel antiNP antinucleocapsid antinucleoprotein
- Product Overview:
Severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein is a viral protein encoded by the N gene in SARS-CoV RNA.{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} The SARS-CoV nucleocapsid protein has a greater than 90% similarity to the SARS-CoV-2 nucleocapsid protein, and SARS-CoV-2 contains 27 T cell epitopes that are identical to SARS-CoV T cell epitopes.{49555} The SARS-CoV nucleocapsid protein packages the viral RNA into a helical ribonucleoprotein complex (RNP) that is a template for viral replication.{53460} It is integral for viral self-assembly and involved with regulation of the cell cycle. SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman’s SARS-CoV Nucleocapsid Protein Polyclonal Antibody can be used for ELISA.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.